Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study
September 28, 2022 09:25 ET
|
Medicenna Therapeutics Corp.
Confirmed partial response in fourth-line metastatic pancreatic cancer patient, who had previously failed chemotherapy and checkpoint inhibitor therapy, supports MDNA11’s single-agent potential in...
Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022
September 22, 2022 07:30 ET
|
Medicenna Therapeutics Corp.
-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer ...
Medicenna Announces Results of Annual Meeting of Shareholders
September 21, 2022 17:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial
September 13, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Present at Investor and Scientific Conferences in September
September 08, 2022 07:30 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today...
Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights
August 15, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
-- Extended Cash Runway Into 2024 With US$20 Million Raise To Complete Phase 1/2 ABILITY Study And Advance Pipeline -- New MDNA11 Data From Dose Escalation in ABILITY Study Shows Tumor Control In...
Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline
August 11, 2022 10:42 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, is pleased to...
Medicenna Announces Pricing of US$20 Million Public Offering of Units
August 09, 2022 09:15 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today...
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units
August 08, 2022 16:15 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today...
Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022
August 05, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...